<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        63-368-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACILOC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        61
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aciloc&trade; contains the active substance omeprazole. It belongs to a group of medicines<br />called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your<br />stomach produces.<br />Aciloc&trade; is used to treat the following conditions:<br />In adults:<br />&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach<br />escapes into the gullet (the tube which connects your throat to your stomach) causing pain,<br />inflammation and heartburn.<br />&bull; Ulcers in the upper part of the intestine (duodenal ulcer) or stomach (gastric ulcer).<br />&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this<br />condition, your doctor may also prescribe antibiotics to treat the infection and allow the<br />ulcer to heal.<br />&bull; Ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).<br />Aciloc&trade; can also be used to stop ulcers from forming if you are taking NSAIDs.<br />&bull; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison<br />syndrome).<br />In children:<br />Children over 1 year of age and &ge; 10 kg<br />&bull; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach<br />escapes into the gullet (the tube which connects your throat to your stomach) causing pain,<br />inflammation and heartburn.<br />In children, the symptoms of the condition can include the return of stomach contents into<br />the mouth (regurgitation), being sick (vomiting) and poor weight gain.<br />Children and adolescents over 4 years of age<br />&bull; Ulcers which are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If your child has this<br />condition, your doctor may also prescribe antibiotics to treat the infection and allow the<br />ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Aciloc&trade;<br />&bull; If you are allergic (hypersensitive) to omeprazole or any of the other ingredients of<br />this medicine (listed in section 6).<br />&bull; If you are allergic to medicines containing other proton pump inhibitors (eg pantoprazole,<br />lansoprazole, rabeprazole, esomeprazole.<br />&bull; If you are taking a medicine containing nelfinavir (used for HIV infection)<br />Do not take Aciloc&trade; if any of the above apply to you. If you are not sure, talk to your<br />doctor or pharmacist before taking Aciloc&trade;.</p><p>Warnings and precautions<br />Talk to your doctor or pharmacist before taking Aciloc&trade;.<br />Aciloc&trade; may hide the symptoms of other diseases. Therefore, if any of the following<br />happen to you before you start taking Aciloc&trade; or while you are taking it, talk to your<br />doctor straight away:<br />&bull; You lose a lot of weight for no reason and have problems swallowing.<br />&bull; You get stomach pain or indigestion.<br />&bull; You begin to vomit food or blood.<br />&bull; You pass black stools (blood-stained faeces).<br />&bull; You experience severe or persistent diarrhoea, as omeprazole has been associated with a<br />small increase in infectious diarrhoea.<br />&bull; You have severe liver problems.<br />&bull; You have ever had a skin reaction after treatment with a medicine similar to Aciloc&trade; that<br />reduces stomach acid.<br />&bull; You are due to have a specific blood test (Chromogranin A).<br />If you take Aciloc&trade; on a long-term basis (longer than 1 year) your doctor will probably<br />keep you under regular surveillance. You should report any new and exceptional symptoms<br />and circumstances whenever you see your doctor.<br />Taking a proton pump inhibitor like Aciloc&trade;, especially over a period of more than one<br />year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if<br />you have osteoporosis or if you are taking corticosteroids (which can increase the risk of<br />osteoporosis).<br />If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as<br />soon as you can, as you may need to stop your treatment with Aciloc&trade;. Remember to also<br />mention any other ill effects like pain in your joints.<br />Interaction with St. John&rsquo;s Wort or Rifampin Drugs which induce CYP2C19 or CYP3A4<br />(such as St. John&rsquo;s Wort or rifampin) can substantially decrease omeprazole concentrations.<br />Avoid concomitant use of ACILOC with St. John&rsquo;s Wort or rifampin.<br />Children<br />Some children with chronic illnesses may require long-term treatment although it is not<br />recommended. Do not give this medicine to children under 1 year of age or &lt; 10 kg.</p><p>Other medicines and Aciloc&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any<br />other medicines. This includes medicines that you buy without a prescription. This is<br />because Aciloc&trade; can affect the way some medicines work and some medicines can have<br />an effect on Aciloc&trade;.<br />Do not take Aciloc&trade; if you are taking a medicine containing nelfinavir (used to treat HIV<br />infection).<br />Tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused<br />by a fungus).<br />&bull; Digoxin (used to treat heart problems).<br />&bull; Diazepam (used to treat anxiety, relax muscles or in epilepsy).<br />&bull; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to<br />monitor you when you start or stop taking Aciloc&trade;.<br />&bull; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers.<br />Your doctor may need to monitor you when you start or stop taking Aciloc&trade;.<br />&bull; Rifampicin (used to treat tuberculosis).<br />&bull; Atazanavir (used to treat HIV infection).<br />&bull; Tacrolimus (in cases of organ transplantation).<br />&bull; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression).<br />&bull; Cilostazol (used to treat intermittent claudication).<br />&bull; Saquinavir (used to treat HIV infection).<br />&bull; Clopidogrel (used to prevent blood clots (thrombi).<br />&bull; Erlotinib (used to treat cancer)<br />&bull; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are<br />taking a high dose of methotrexate, your doctor may temporarily stop your Aciloc&trade;<br />treatment.<br />If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as<br />Aciloc&trade; to treat ulcers caused by Helicobacter pylori infection, it is very important that<br />you tell your doctor about any other medicines you are taking.<br />Taking Aciloc&trade; with food and drink<br />See section 3.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a<br />baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Omeprazole is excreted in breast milk but is not likely to influence the child when<br />therapeutic doses are used.<br />Your doctor will decide whether you can take Aciloc&trade; if you are breast-feeding.<br />Driving and using machines<br />Aciloc&trade; is not likely to affect your ability to drive or use any tools or machines.<br />Side effects such as dizziness and visual disturbances may occur (see section 4). If affected,<br />you should not drive or operate machinery.<br />Important information about some of the ingredients of Aciloc&trade;<br />If you have been told by your doctor that you have an intolerance to some sugars, contact<br />your doctor before taking this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Aciloc&trade; exactly as your doctor or pharmacist has told you. You should check<br />with your doctor or pharmacist if you are not sure.<br />Your doctor will tell you how many capsules to take and how long to take them for. This<br />will depend on your condition and how old you are.<br />The recommended dose is given below.<br />Use in adults<br />To treat symptoms of GORD such as heartburn and acid regurgitation:<br />&bull; If your doctor has found that your food pipe (gullet) has been slightly damaged, the<br />recommended dose is 20 mg once a day for 4-8 weeks. Your doctor may tell you to take a<br />dose of 40 mg for a further 8 weeks if your gullet has not yet healed.<br />&bull; The recommended dose once the gullet has healed is 10 mg once a day.<br />&bull; If your gullet has not been damaged, the usual dose is 10 mg once a day.<br />To treat ulcers in the upper part of the intestine (duodenal ulcer):<br />&bull; The recommended dose is 20 mg once a day for 2 weeks. Your doctor may tell you to take<br />the same dose for a further 2 weeks if your ulcer has not yet healed.<br />&bull; If the ulcer do not fully heal, the dose can be increased to 40 mg once a day for 4 weeks.<br />To treat ulcers in the stomach (gastric ulcer):<br />&bull; The usual dose is 20 mg once a day for 4 weeks. Your doctor may tell you to take the<br />same dose for a further 4 weeks if your ulcer has not yet healed.<br />&bull; If the ulcers do not fully heal, the dose can be increased to 40 mg once a day for 8 weeks.<br />To prevent the duodenal and stomach ulcers from coming back:<br />&bull; The usual dose is 10 mg or 20 mg once a day. Your doctor may increase the dose to 40<br />mg once a day.<br />To treat duodenal and stomach ulcers caused by NSAIDs (Non-Steroidal<br />Anti-Inflammatory Drugs):<br />&bull; The usual dose is 20 mg once a day for 4&ndash;8 weeks.<br />To prevent duodenal and stomach ulcers if you are taking NSAIDs<br />&bull; The recommended dose is 20 mg once a day.<br />To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:<br />&bull; The recommended dose is 20 mg Aciloc&trade; twice a day for one week.<br />&bull; Your doctor will also tell you to take two antibiotics among amoxicillin, clarithromycin<br />and metronidazole.<br />To treat too much acid in the stomach caused by a growth in the pancreas<br />(Zollinger-Ellison syndrome):<br />&bull; The recommended dose is 60 mg daily.<br />&bull; Your doctor will adjust the dose depending on your needs and will also decide how long<br />you need to take the medicine for.<br />Use in children and adolescents<br />To treat symptoms of GORD such as heartburn and acid regurgitation:</p><p>&bull; Children over 1 year of age and with a body weight of more than 10 kg may take<br />Aciloc&trade;. The dose for children is based on the child&rsquo;s weight and the doctor will decide the<br />correct dose.<br />To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:<br />&bull; Children aged over 4 years may take Aciloc&trade;. The dose for children is based on the<br />child&rsquo;s weight and the doctor will decide the correct dose.<br />&bull; Your doctor will also prescribe two antibiotics called amoxicillin and clarithromycin for<br />your child.<br />Taking this medicine<br />&bull; It is recommended that you take your capsules in the morning.<br />&bull; You can take your capsules with food or on an empty stomach.<br />&bull; Swallow your capsules whole with half a glass of water. Do not chew or crush the<br />capsules. This is because the capsules contain coated pellets which stop the medicine from<br />being broken down by the acid in your stomach. It is important not to damage the pellets.<br />What to do if you or your child have trouble swallowing the capsules<br />&bull; If you or your child have trouble swallowing the capsules:<br />- Open the capsules and swallow the contents directly with half a glass of water or put the<br />contents into a glass of still (non-fizzy) water, any acidic fruit juice (e.g. apple, orange or<br />pineapple) or apple sauce.<br />- Always stir the mixture just before drinking it (the mixture will not be clear). Then drink<br />the mixture straight away or within 30 minutes.<br />- To make sure that you have drunk all of the medicine, rinse the glass very well with half a<br />glass of water and drink it. The solid pieces contain the medicine do not chew or crush<br />them.<br />If you take more Aciloc&trade; than you should<br />If you take more Aciloc&trade; than prescribed by your doctor, talk to your doctor or pharmacist<br />straight away.<br />If you forget to take Aciloc&trade;<br />If you forget to take a dose, take it as soon as you remember it. However, if it is almost time<br />for your next dose, skip the missed dose. Do not take a double dose to make up for a<br />forgotten dose.<br />If you stop taking Aciloc&trade;<br />Do not stop taking Aciloc&trade; without first talking to your doctor or pharmacist.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Aciloc&trade; can cause side effects, although not everybody gets them.<br />If you notice any of the following rare but serious side effects, stop taking Aciloc&trade; and<br />contact a doctor immediately:<br />&bull; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or<br />difficulties in swallowing (severe allergic reaction).<br />&bull; Reddening of the skin with blisters or peeling. There may also be severe blisters and<br />bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson<br />syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.<br />&bull; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.<br />Other side effects include:<br />Common side effects (may affect up to 1 in 10 people)<br />&bull; Headache.<br />&bull; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).<br />&bull; Feeling sick (nausea) or being sick (vomiting).<br />&bull; Benign polyps in the stomach.<br />Uncommon side effects (may affect up to 1 in 100 people)<br />&bull; Swelling of the feet and ankles.<br />&bull; Disturbed sleep (insomnia).<br />&bull; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.<br />&bull; Spinning feeling (vertigo).<br />&bull; Changes in blood tests that check how the liver is working.<br />&bull; Skin rash, lumpy rash (hives) and itchy skin.<br />&bull; Generally feeling unwell and lacking energy.<br />Rare side effects (affects 1 to 10 users in 10,000)<br />&bull; Blood problems such as a reduced number of white cells or platelets. This can cause<br />weakness, bruising or make infections more likely.<br />&bull; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and<br />throat, fever, wheezing.<br />&bull; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and<br />cramps. &bull; Feeling agitated, confused or depressed. &bull; Taste changes.<br />&bull; Eyesight problems such as blurred vision.<br />&bull; Suddenly feeling wheezy or short of breath (bronchospasm).<br />&bull; Dry mouth. &bull; An inflammation of the inside of the mouth.<br />&bull; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.<br />&bull; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.<br />&bull; Hair loss (alopecia). &bull; Skin rash on exposure to sunshine.<br />&bull; Joint pains (arthralgia) or muscle pains (myalgia).<br />&bull; Severe kidney problems (interstitial nephritis). &bull; Increased sweating.</p><p>Very rare side effects (affects less than 1 user in 10,000)<br />&bull; Changes in blood count including agranulocytosis (lack of white blood cells).<br />&bull; Aggression. &bull; Seeing, feeling or hearing things that are not there (hallucinations).<br />&bull; Severe liver problems leading to liver failure and inflammation of the brain.<br />&bull; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a<br />high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic<br />epidermal necrolysis). &bull; Muscle weakness. &bull; Enlarged breasts in men.<br />Not known (frequency cannot be estimated from the available data)<br />&bull; If you are on Aciloc&trade; for more than three months it is possible that the levels of<br />magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue,<br />involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart<br />rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of<br />magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your<br />doctor may decide to perform regular blood tests to monitor your levels of magnesium.<br />&bull; Rash, possibly with pain in the joints.<br />Aciloc&trade; may in very rare cases affect the white blood cells leading to immune deficiency.<br />If you have an infection with symptoms such as fever with a severely reduced general<br />condition or fever with symptoms of a local infection such as pain in the neck, throat or<br />mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a<br />lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important<br />for you to give information about your medicine at this time.<br />Do not be concerned by this list of possible side effects. You may not get any of them. If<br />any of the side effects get serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &deg;C.<br />&bull; Do not use Aciloc&trade; after the expiry date which is stated on the pack after EXP.<br />&bull; Store this blister in the original package.<br />&bull; Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help to<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is omeprazole. Aciloc&trade; hard gastro-resistant capsules contain<br />10 mg or 20 mg or 40 mg of omeprazole.<br />- The other ingredients are Sugar Spheres, Hypromellose, Talc, Sodium Hydroxide,<br />Methacrylic acid Ethyl acrylate, Macrogol, Titanium dioxide, Iron Oxide Red and Gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Aciloc™ 10 mg capsules: Pink cap / Pink body hard gelatin capsule imprinted with
'Jamjoom' on cap and 'OME 10' on body, filled with white to off white pellets.
• Aciloc™ 20 mg capsules: Reddish brown cap / Pink body hard gelatin capsules imprinted
with 'Jamjoom' on cap and 'OME 20' on body, filled with white to off white pellets.
• Aciloc™ 40 mg capsules: Reddish brown cap / Reddish brown body hard gelatin capsules
imprinted with 'Jamjoom' on cap and 'OME 40' on body, filled with white to off white
pellets.
Aciloc™ 10 mg comes in packs of 7 & 14 capsules.
Aciloc™ 20 mg comes in packs of 7 & 14 & 28 capsules.
Aciloc™ 40 mg comes in packs of 7 & 14 & 28 capsules.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111<br />Fax: +966-12-6081222<br />Website: www.jamjoompharma.com</p><p>Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed at 09/2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>على أومیبرازول كمادة فعالة وھي تنتمي إلى فئة من الأدویة تسمى &quot;مثبطات مضخة البروتون&quot; &trade; یحتوي أسیلوك<br />وھي تعمل على تقلیل كمیة الحمض الذي تنتجھ المعدة.<br />لعلاج الحالات الآتیة: &trade; یستخدم أسیلوك<br />للبالغین:<br />- الارتجاع المعدي المریئي حیث یھرب الحمض من داخل المعدة إلى المرئ (قناة تصل بین المعدة والحلق) مما<br />یسبب الألم والالتھاب وحرقة المعدة.<br />- قرحة في الجزء العلوي من الأمعاء (الإثنا عشر) أو المعدة.<br />- القرح التي تسببھا عدوى بكتیریا تسمى (ھیلیكوباكتر بایلوري). إذا كنت مصابا بھذه الحالة فمن الممكن أن یصف<br />الطبیب لك مضادا حیویا لعلاج العدوى ومن ثم یمكن للقرحة ان تلتئم.<br />أن یوقف &trade; - القرح التي تسببھا فئة من الأدویة تسمى الأدویة غیر الستیرودیة والمضادة للالتھاب . یمكن لأسیلوك<br />تكون القرح إذا كنت تستخدم الأدویة غیر الستیرودیة والمضادة للالتھاب.<br />- زیادة إفراز الحمض في المعدة الذي یسببھ ورم في البنكریاس (متلازمة زولینجر إلیسون).<br />للأطفال:<br />الأطفال الأكبر من عام و یزنون ۱۰ كجم أو أكثر<br />- الارتجاع المعدي المریئي حیث یھرب الحمض من داخل المعدة إلى المرئ (قناة تصل بین المعدة والحلق) مما<br />یسبب الألم والالتھاب وحرقة المعدة.<br />قد تشتمل الأعراض عند الأطفال على ارتجاع محتوى المعدة داخل الفم (الاجترار)، الشعور بالغثیان (القئ)،<br />انخفاض معدل زیادة الوزن.<br />الأطفال الأكبر والمراھقین الأكبر من ٤ أعوام<br />- القرح التي تسببھا عدوى بكتیریا تسمى (ھیلیكوباكتر بایلوري). إذا كان طفلك مصابا بھذه الحالة فمن الممكن أن<br />یصف الطبیب لھ مضادا حیویا لعلاج العدوى ومن ثم یمكن للقرحة ان تلتئم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- إذا كنت تعاني من فرط الحساسیة ضد أومیبرازول أو أي مكون آخر من مكونات ھذا الدواء (مدرج في القسم ٦<br />- إذا كان لدیك حساسیة تجاه أي دواء آخر یحتوي علي مثبطات مضخة البروتون مثل بانتوبرازول، لانسوبرازول،<br />رابیبرازول، ایسومیبرازول.<br />- إذا كنت تستخدم دواء یحتوي علي مادة نیلفینافیر [تستخدم في حالات فیروس نقص المناعة المكتسب (الإیدز)].<br />إذا كان أي مما سبق ینطبق علیك. إذا كنت غیر متأكد استشر طبیبك أو الصیدلي قبل استخدامك &trade; لا تستخدم أسیلوك<br />&trade; أسیلوك<br />المحاذیر والإحتیاطات<br />&trade; تحدث إلى طبیبك أو الصیدلي قبل تناول أسیلوك<br />أعراض الأمراض الأخرى ولذلك إذا حدث لك أي شئ من الأشیاء التالیة بمجرد بدء &trade; من الممكن أن یخفي أسیلوك<br />استخدام الدواء أو أثناء استخدامھ استشر طبیبك علي الفور:<br />- لاحظت فقدان الوزن بدون سبب ومشاكل في البلع.<br />- ألم في المعدة او عسر الھضم.<br />- إذا بدأت في تقیؤ الطعام او الدم.<br />- كان لون البراز أسود (براز مخضب بالدم).<br />- إذا أصبت بإسھال شدید أو مستمر حیث أن أومیبرازول یكون مصحوب بزیادة في حدوث الإسھال المعدي.<br />- كان لدیك مشاكل حادة في الكبد.<br />الذي یقلل من حموضة المعدة. &trade; - عانیت من قبل من رد فعل جلدي بعد العلاج بدواء مشابھ لأسیلوك<br />- من المقرر أن تخضع لفحص دم محدد (كروموجرانین أ).<br />على المدى الطویل ، خصوصا لو كان ذلك لفترة أطول من عام، فمن المحتمل ان &trade; إذا قمت باستخدام أسیلوك<br />یضعك الدكتور تحت الملاحظة المنتظمة باستمرار. یجب علیك إبلاغ الطبیب عند زیارتھ عن أي أعراض أو ظروف<br />جدیدة أو استثنائیة.<br />خاصة على مدى أكثر من عام ، إلى زیادة طفیفة في ، &trade; قد یؤدي تناول مثبطات مضخة البروتون مثل أسیلوك<br />خطر تعرضك لكسر في الورك أو الرسغ أو العمود الفقري. أخبر طبیبك إذا كنت تعاني من ھشاشة العظام أو إذا كنت<br />تتناول الكورتیكوستیرویدات (والتي یمكن أن تزید من خطر الإصابة بھشاشة العظام).<br />إذا أصبت بطفح جلدي على جلدك ، خاصة في المناطق المعرضة للشمس ، أخبر طبیبك بأسرع ما یمكن ، فقد تحتاج<br />تذكر أیضًا أن تذكر أي آثار سیئة أخرى مثل ألم المفاصل. .&trade; إلى إیقاف العلاج باستخدام أسیلوك<br />مثل نبتة سانت جون أو ) CYP3A أو 4 CYP2C التفاعل مع أدویة نبتة سانت جون أو ریفامبین التي تحفز 19<br />ریفامبین) یمكن أن تقلل بشكل كبیر من تركیزات أومیبرازول.<br />مع نبتة سانت جون أو ریفامبین. &trade; تجنب الاستخدام المتزامن ل أسیلوك<br />الأطفال<br />قد یحتاج بعض الأطفال المصابین بأمراض مزمنة إلى علاج طویل الأمد رغم أن ھذا غیر موصى بھ. لا تعط ھذا<br />الدواء للأطفال أقل من سنة أو أقل من ۱۰ كجم.<br />&trade; الأدویة الأخرى و أسیلوك<br />أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدویة أخرى. وھذا یشمل الأدویة التي<br />یمكن أن یؤثر على طریقة عمل بعض الأدویة ویمكن أن یكون &trade; تشتریھا بدون وصفة طبیة. وذلك لأن أسیلوك<br />.&trade; لبعض الأدویة تأثیر على أسیلوك<br />إذا كنت تستخدم دواء یحتوي على مادة نیلفینافیر [تستخدم في حالات فیروس نقص المناعة &trade; لا تتناول أسیلوك<br />المكتسب (الإیدز)].<br />أخبر طبیبك أو الصیدلي إذا كنت تتناول أي من الأدویة التالیة:<br />- كیتوكونازول، ایتراكونازول، بوساكونازول أو فوریكونازول (تستخدم لعلاج عدوى الفطریات).<br />- دیجوكسین (یستخدم لعلاج مشاكل القلب).<br />- دیازیبام (یستخدم في علاج القلق، باسط للعضلات، الصرع).<br />- فینیتوین (یستخدم في علاج الصرع). إذا كنت تستخدم فینیتوین سیحتاج الطبیب لوضعك تحت الملاحظة بعد توقفك<br />&trade; عن تناول أسیلوك<br />- الأدویة التي تستخدم لتمییع الدم ومنع تخثره مثل الوارفارین أو حاصرات فیتامین ك الأخرى. سیحتاج الطبیب<br />&trade; لوضعك تحت الملاحظة بعد توقفك عن تناول أسیلوك<br />- ریفامبیسین (یستخدم لعلاج السل).<br />- أتازانافیر [یستخدم في حالات فیروس نقص المناعة المكتسب (الإیدز)].<br />- تاكرولیماس (في حالات زرع الأعضاء).<br />- نبتة سنات جونز او حشیشة القلب (ھایبریكام بیرفوراتام) (تستخدم في علاج الاكتئاب البسیط).<br />- سیلوستازول (یستخدم في علاج العرج المتقطع).<br />- ساكوینافیر[یستخدم في حالات فیروس نقص المناعة المكتسب (الإیدز)].<br />- كلوبیدوجریل (یمنع تكون جلطات الدم).<br />&bull; إرلوتینیب (یستخدم لعلاج السرطان)<br />&bull; میثوتریكسات (دواء من العلاج الكیمیائي یستخدم بجرعات عالیة لعلاج السرطان) - إذا كنت تتناول جرعة عالیة<br />مؤقتًا. &trade; من میثوتریكسات ، فقد یوقف طبیبك علاج أسیلوك<br />لعلاج القرحة الناتج &trade; إذا وصف لك الطبیب مضاد حیوي مثل الأموكسیسیللین أو الكلاریثرومایسین بجانب أسیلوك<br />عن بكتیریا الھیلیكوباتر بایلوري، من المھم جدا أن تخبر طبیبك حول الأدویة الأخرى التي تتناولھا.<br />مع الطعام والشراب &trade; تناول أسیلوك<br />. انظر القسم ۳<br />الحمل والرضاعة والخصوبة<br />إذا كنت حاملاً أو مرضعة ، تعتقدین أنك حامل أو تخططین لإنجاب طفل ، اسألي طبیبك أو الصیدلي للحصول على<br />المشورة قبل تناول ھذا الدواء. یفرز أومیبرازول في حلیب الثدي ولكن لیس من المحتمل أن یؤثر على الطفل عند<br />استخدام الجرعات العلاجیة.<br />من عدمھ إذا كنتِ مرضعة. &trade; سیقرر الطبیب إمكانیة تناول أسیلوك<br />قیادة المركبات وتشغیل الآلات<br />على قدرتك على قیادة المركبات أو تشغیل المعدات.قد تحدث بعض الآثار &trade; من غیر المحتمل أن یؤثر أسیلوك<br />الجانبیة مثل الدوخة أو اضطراب في الرؤیة وفي ھذه الحالات یجب الامتناع عن قیادة السیارات أو تشغیل الآلات.<br />&trade; معلومات ھامة حول بعض مكونات أسیلوك<br />علي اللاكتوز. إذا كان قد تم إخبارك بواسطة طبیبك عن أنك لدیك حساسیة ضد بعض &trade; تحتوي كبسولات أسیلوك<br />السكریات فیجب علیك استشارة الطبیب قبل استخدام ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>وفقا لما یخبرك بھ الطبیب أو الصیدلي. یجب علیك مراجعة الطبیب أو الصیدلي إذا لم &trade; یجب أن یكون تناول أسیلوك<br />تكن متأكدا.<br />سیخبرك الطبیب بعدد الكبسولات التي ستتناولھا والمدة التي ستتناول فیھا الدواء. حسب حالتك وعلى عمرك.<br />الجرعات الموصى بھا موضحة بالأسفل.<br />الإستخدام مع البالغین:<br />لعلاج أعراض الارتجاع المعدي المریئي مثل حرقة المعدة واجترار الحمض:<br />- إذا وجد طبیبك أن قناة الطعام (المرئ) قد أصابھا بعض التلف تكون الجرعة الموصى بھا ھي ۲۰ ملجم مرة واحدة<br />۸ أسابیع. من الممكن أن یصف لك الطبیب جرعة ٤۰ ملجم لمدة ۸ أسابیع أخرى في حالة عدم - في الیوم ولمدة ٤<br />التئام المرئ.<br />- الجرعة الموصى بھا بمجرد شفاء المريء ھي ۱۰ ملجم مرة واحدة في الیوم.<br />&bull; إذا لم یتضرر المريء ، فإن الجرعة المعتادة ھي ۱۰ ملجم مرة في الیوم.<br />لعلاج قرح الجزء العلوي من الأمعاء (قرحة الاثنا عشر):<br />- الجرعة الموصى بھا ھي ۲۰ ملجم مرة واحدة في الیوم ولمدة أسبوعین. من الممكن أن یصف لك الطبیب نفس<br />الجرعة لمدة أسبوعین آخرین في حالة عدم التئام القرحة.<br />- إذا لم تلتئم القرحة بشكل كامل یمكن زیادة الجرعة إلى ٤۰ ملجم مرة واحدة في الیوم ولمدة ٤ أسابیع.<br />لعلاج قرحة المعدة:<br />- الجرعة الموصى بھا ھي ۲۰ ملجم مرة واحدة في الیوم ولمدة ٤ أسابیع. من الممكن أن یصف لك الطبیب نفس<br />الجرعة لمدة ٤ أسابیع أخرى في حالة عدم التئام القرحة.<br />- إذا لم تلتئم القرحة بشكل كامل یمكن زیادة الجرعة إلى ٤۰ ملجم مرة واحدة في الیوم ولمدة ۸ أسابیع.<br />لمنع عودة حدوث قرحة المعدة والاثني عشر:<br />- الجرعة الموصى بھا ھي ۱۰ ملجم أو ۲۰ ملجم مرة واحدة یومیا. قد یزید الطبیب الجرعة لتصبح ٤۰ ملجم مرة<br />واحدة یومیا.<br />لعلاج قرحة المعدة والاثنى عشر التي تتسبب فیھا الأدویة غیر الستیرودیة والمضادة للالتھاب:<br />۸ أسابیع. - - الجرعة الموصى بھا ھي ۲۰ ملجم مرة واحدة یومیا لمدة ٤<br />لمنع عودة حدوث قرحة المعدة والاثني عشر التي تتسبب فیھا الأدویة غیر الستیرودیة والمضادة للالتھاب:<br />- الجرعة الموصى بھا ھي ۲۰ ملجم مرة واحدة یومیا<br />لعلاج القرح التي تتسبب فیھا بكتیریا ھیلیكوباكتر بایلوري ولمنع عودة حدوثھا مرة أخرى:<br />- الجرعة الموصى بھا ھي ۲۰ ملجم مرتین یومیا ولمدة أسبوع.<br />- سیصف لك الطبیب أیضا استخدام اثنین من المضادات الحیویة: أموكسیسیللین، كلاریثرومایسن، میترونیدازول.<br />لعلاج فرط إفراز الحمض داخل المعدة بسبب ورم في البنكریاس (متلازمة زولینجر إیلیسون):<br />- الجرعة الموصى بھا ھي ٦۰ ملجم یومیا<br />- سیقوم الطبیب بتعدیل الجرعة وفقا لحالتك واحتیاجك وسیحدد أیضا الفترة التي ستستمر في تناول الدواء خلالھا.<br />الإستخدام مع الأطفال و المراھقین:<br />لعلاج أعراض الارتجاع المعدي المریئي مثل حرقة المعدة واجترار الحمض:<br />تعتمد الجرعة في ھذه الحالة .&trade; - الأطفال الاكبر من عام ویزنون اكثر من ۱۰ كجم من الممكن</p><p>لعلاج القرح التي تتسبب فیھا بكتیریا ھیلیكوباكتر بایلوري ولمنع عودة حدوثھا مرة أخرى:<br />تعتمد الجرعة في ھذه الحالة علي وزن الطفل ویقوم .&trade; - الأطفال الأكبر من ٤ أعوام من الممكن أن یتعاطوا أسیلوك<br />الطبیب بتحدید الجرعة الصحیحة.<br />- سیصف الطبیب لطفلك استخدام اثنین من المضادات الحیویة ھما أموكسیسیللین، كلاریثرومایسن.</p><p>- ینصح بتناول ھذه الكبسولات عند الصباح.<br />- یمكنك تناول الكبسولات مع الطعام أو على معدة خالیة.<br />- ابلع كامل الكبسولة مع نصف كوب من الماء. لا تمضغ أو تطحن الكبسولة وھذا بسبب أن ھذه الكبسولة تحتوي على<br />كریات مغلفة تحمي الدواء من أن یتم تكسیره بواسطة الحمض في المعدة. من المھم أن لا تقوم بإتلاف ھذه الكریات.<br />ماذا تفعل إذا كان لدیك أو لدى طفل مشاكل في بلع الكبسولات؟<br />إذا كان لدیك أو لدى طفلك مشاكل في بلع الكبسولات.<br />- افتح الكبسولة وابتلع محتویاتھا مباشرة مع نصف كوب من الماء، أو ضع محتویاتھا في كوب من الماء (غیر الغازي)<br />أو أي عصیر حامضي مثل البرتقال أو التفاح أو الأناناس أو صوص التفاح.<br />- دائما قم بتقلیب الخلیط (الخلیط لن یكون نقیا) ثم قم بشرب الخلیط مباشرة أو خلال ۳۰ دقیقة.<br />- للتأكد من أنك قمت ببلع كامل كمیة الدواء قم بشطف الكوب بنصف كوب من الماء بشكل جید ثم اشربھ. الأجزاء<br />الصلبة تكون محتویة علي دواء.لا تقم بتحطیمھا أو مضغھا.<br />بكمیة أكثر مما ینبغي &trade; إذا تناولت أسیلوك<br />بكمیة أكثر مما وصفھ لك الطبیب، اتصل بطبیبك أو الصیدلي فوراً. &trade; إذا تناولت أسیلوك<br />&trade; إذا نسیت أن تتناول أسیلوك<br />إذا نسیت موعد الجرعة فقم بتناولھا فور أن تتذكر، فإذا كان موعد الجرعة التالیة قد حان فقم بالغاء الجرعة التي نسیتھا.<br />لا تتناول ضعف الجرعة لكي تعوض الجرعة الفائتة.<br />&trade; إذا توقفت عن تتناول أسیلوك<br />دون التحدث مع طبیبك أو الصیدلي. &trade; لا تتوقف عن تناول أسیلوك<br />إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ن یتسبب في تأثیرات جانبیة ولكنھا لا تصیب كل الأشخاص. &trade; كما ھو الحال مع كل الأدویة، یمكن ل أسیلوك<br />واتصل بالطبیب &trade; إذا لا حظت ظھور أي من الأعراض الجانبیة التالیة النادرة والخطیرة توقف عن استخدام أسیلوك<br />على الفور:<br />- صفیر مفاجئ، تورم (الشفاة، اللسان، الحلق، الجسم)، طفح جلدي، إغماء، صعوبة في البلع (تفاعل تحسسي حاد).<br />- احمرار الجلد مع وجود بثور أو تقشر. من الممكن أیضا ان یكون ھناك بثور حادة ونزیف في الشفاة، العیون، الفم،<br />الأنف، الأعضاء التناسلیة. من الممكن أن یكون ذلك ھو متلازمة ستیفین جونسون أو انحلال البشرة السمي.<br />- الجلد الأصفر، البول الداكن، الإجھاد من الممكن أن یكونوا أعراض لمشاكل في الكبد.<br />الآثار الجانبیة الأخرى<br />أعراض جانبیة شائعة (قد تظھر حتى ۱ من كل ۱۰ أشخاص)<br />- الصداع. - تأثیرات علي المعدة أو الجھاز الھضمي: إسھال، ألم في المعدة، إمساك، ریح (انتفاخ).<br />- الشعور بالغثیان أو القئ. - الاورام الحمیدة في المعدة.<br />أعراض جانبیة غیر شائعة (قد تظھر حتى ۱ من كل ۱۰۰ أشخاص)<br />- تورم القدم و الكاحل. - اضطراب النوم (الأرق).<br />- الدوخة، الشعور بالوخز (مثل وخز الإبر والدبابیس)، الشعور بالنعاس.<br />- الشعور بالدوار. - تغیرات في نتائج اختبارات الدم التي تدل على سلامة وظائف الكبد.<br />- طفح جلدي، طفح عُقدي (أرتیكاریا)، حكة في الجلد. - الشعور بالتعب وفقدان الطاقة.<br />۱۰ أشخاص من أصل ۱۰۰۰۰ یستخدمون الدواء) - نادرة (یصاب من ۱<br />- مشاكل في الدم مثل انخفاض عدد خلایا الدم البیضاء أو الصفائح الدمویة. من الممكن أن یتسبب ذلك في الشعور<br />بالضعف، الكدمات، سھولة الإصابة بالعدوى.<br />- تفاعل تحسسي، یكون حادا في بعض الاحیان ویشمل تورم في (الشفاة، اللسان، الحلق)، حمى، صفیر.<br />- انخفاض معدل الصودیوم في الدم وھو ما یمكن أن یتسبب في الضعف أو القئ أو تقلصات في العضلات.<br />- الشعور بالھیاج أو التوتر أو الاكتئاب.<br />- تغیرات في حاسة التذوق. - مشاكل في الرؤیة مثل عدم وضوح الرؤیة.<br />- ضیق النفس مع الشعور بالصفیر (انقباض في الشعب الھوائیة).<br />- جفاف في الفم. - التھاب داخل الفم.<br />- الإصابة بعدوى تسمى &quot;القلاع&quot; والتي تصیب القناة الھضمیة ویتسبب فیھا أحد الفطریات.<br />- مشاكل في الكبد بما في ذلك الصفراء والتي تشمل اصفرار في الجلد وبول داكن والشعور بالتعب.<br />- سقوط الشعر (الصلع). - طفح جلدي عن التعرض لأشعة الشمس.<br />- آلام في المفاصل والعضلات. - مشاكل حادة في الكلى. - زیادة إفراز العرق.<br />نادرة جدا (یصاب بھا أقل من ۱ من أصل ۱۰۰۰۰ شخص یستخدمون الدواء)<br />- تغیرات في عدد خلایا الدم بما في ذلك ما یسمى بندرة المحببات (نقص عدد خلایا الدم البیضاء).<br />- العدوانیة. - رؤیة أو سماع أو الشعور بأشیاء غیر موجودة (الھلوسة).<br />- مشاكل حادة في الكبد تؤدي إلى فشل في وظائف الكبد والتھاب في المخ.<br />- ظھور مفاجئ لطفح جلدي أو بثور أو تقشر في الجلد.من الممكن ان یكون ذلك مصحوبا بحمى شدیدة وآلام في<br />المفاصل (حُمامى عدیدة الأشكال، متلازمة ستیفن جونز، انحلال البشرة النخري)<br />- ضعف في العضلات. - تضخم في الثدي عند الرجال.<br />غیر معروفة (لا یمكن توقع معدل تكرارھا من البیانات المتاحة).<br />منذ أكثر من ۳ أشھر فمن الممكن ان یھبط مستوى الماغنسیوم في الدم. انخفاض مستوى &trade; - إذا كنت تتناول أسیلوك<br />الماغنسیوم یظھر علي شكل إجھاد ، انقباضات لا إرادیة في العضلات، التوھان، تشنجات، دوخة، ازدیاد معدل<br />ضربات القلب.<br />إذا كان لدیك أحد ھذه الأعراض أخبر طبیبك على وجھ السرعة.<br />انخفاض مستوى الماغنسیوم في الدم قد یؤدي أیضا إلي انخفاض في مستویات الكالسیوم والبوتاسیوم. قد ینصحك<br />الطبیب بعمل فحوصات دوریة للدم لمراقبة مستوى الماغنسیوم.<br />&bull; طفح جلدي ، وربما مع ألم في المفاصل.<br />على خلایا الدم البیضاء بما یؤدي إلي نقص في المناعة. إذا كان لدیك &trade; في بعض الحالات النادرة جدا قد یؤثر أسیلوك<br />عدوي مع اعراض مثل الحمى مع انخفاض حاد في الحالة العامة أو حمى مع أعراض عدوى موضعیة مثل آلام في<br />الرقبة أو الحلق أو الفم أو صعوبة في التبول، یجب علیك استشارة الطبیب بأقصى سرعة ممكنة ولھذا فإن نقص خلایا<br />الدم البیضاء (ندرة المحببات) یمكن استبعاده عن طریق عمل اختبار أو تحلیل للدم. من المھم أن تعطي معلومات حول<br />دوائك في ھذا التوقیت.<br />لا تقلق من ھذه القائمة الخاصة بالأعراض الجانبیة فقد لا یصیبك أیا منھا. إذا وصلت أیا من ھذه الأعراض لدرجة<br />الخطورة أو لاحظت ظھور أعراض أخرى غیر مذكورة في ھذه النشرة، یرجى اخبار الطبیب أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ بعیداً عن متناول و مرأى الأطفال .<br />&bull; یحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />.EXP بعد تاریخ انتھاء الصلاحیة المدون على العبوة بعد &trade; &bull; لا تستخدم أسیلوك<br />&bull; قم بتخزین الشریط داخل العلبة الأصلیة.<br />&bull; لا ینبغي التخلص من الأدویة عبر بالوعات الصرف أو ضمن مخلفات المنزل. اسأل الصیدلي الخاص بك عن طریقة<br />التخلص من الأدویة التي لم تعد بحاجة إلیھا. ستساعد ھذه التدابیر في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المقاومة للعصارة الھضمیة على &trade; المادة فعالة ھي أومیبرازول. تحتوي كبسولات أسیلوك<br />۱۰ ملجم أو ۲۰ ملجم أو ٤۰ ملجم من الأومیبرازول.<br />- المكونات الأخرى ھي: كریات سكر ، ھیبرومیلوز ، تلك ، ھیدروكسید الصودیوم ، حمض میثاكریلیك ، إیثیل<br />أكریلیت ، ماكروغول ، ثاني أكسید التیتانیوم ، أكسید الحدید الأحمر و جیلاتین.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>۱۰ ملجم ذات جزء علوي وردي اللون والجزء الآخر السفلي وردي اللون مطبوع علیھا &trade; - كبسولات أسیلوك<br />على الجزء السفلي، ملیئة بحبیبات لونھا أبیض إلى مائل للأبیض. &#39;OME على الجزء العلوي و &#39; 10 &#39;Jamjoom&#39;<br />۲۰ ملجم ذات جزء علوي بني محمر اللون والجزء الآخر السفلي وردي اللون مطبوع علیھا &trade; - كبسولات أسیلوك<br />على الجزء السفلي، ملیئة بحبیبات لونھا أبیض إلى مائل للأبیض. &#39;OME على الجزء العلوي و &#39; 20 &#39;Jamjoom&#39;<br />٤۰ ملجم ذات جزء علوي بني محمر اللون والجزء الآخر السفلي بني محمر اللون مطبوع علیھا &trade; - كبسولات أسیلوك<br />على الجزء السفلي، ملیئة بحبیبات لونھا أبیض إلى مائل للأبیض. &#39;OME على الجزء العلوي و &#39; 40 &#39;Jamjoom&#39;<br />۱٤ كبسولة . ، ۱۰ ملجم، عبوة تحتوى على ۷ &trade; أسیلوك<br />۲۸ كبسولة . ،۱٤ ، ۲۰ ملجم، عبوة تحتوى على ۷ &trade; أسیلوك<br />۲۸ كبسولة. ،۱٤ ، ٤۰ ملجم، عبوة تحتوى على ۷ &trade; أسیلوك</p><p>&nbsp;</p><p>قد لا تكون كل أحجام العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aciloc 40 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 40 mg Omeprazole.
Excipients:
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aciloc 40 capsules are indicated for:<br />Adults<br />&bull; Treatment of duodenal ulcers<br />&bull; Prevention of relapse of duodenal ulcers<br />&bull; Treatment of gastric ulcers<br />&bull; Prevention of relapse of gastric ulcers<br />&bull; In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic<br />ulcer disease<br />&bull; Treatment of NSAID-associated gastric and duodenal ulcers<br />&bull; Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk<br />&bull; Treatment of reflux oesophagitis<br />&bull; Long-term management of patients with healed reflux oesophagitis</p><p>&bull; Treatment of symptomatic gastro-oesophageal reflux disease<br />&bull; Treatment of Zollinger-Ellison syndrome<br />Paediatric use<br />Children over 1 year of age and 10 kg<br />&bull; Treatment of reflux oesophagitis<br />&bull; Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease<br />Children and adolescents over 4 years of age<br />&bull; In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />Treatment of duodenal ulcers<br />The recommended dose in patients with an active duodenal ulcer is Aciloc 20 mg once daily. In most<br />patients healing occurs within two weeks. For those patients who may not be fully healed after the initial<br />course, healing usually occurs during a further two weeks treatment period. In patients with poorly<br />responsive duodenal ulcer Aciloc 40 mg once daily is recommended and healing is usually achieved<br />within four weeks.</p><p>Prevention of relapse of duodenal ulcers<br />For the prevention of relapse of duodenal ulcer in H. pylori negative patients or when H.<br />pylori eradication is not possible the recommended dose is Aciloc 20 mg once daily. In some patients a<br />daily dose of 10 mg may be sufficient. In case of therapy failure, the dose can be increased to 40 mg.</p><p>Treatment of gastric ulcers<br />The recommended dose is Aciloc 20 mg once daily. In most patients healing occurs within four weeks.<br />For those patients who may not be fully healed after the initial course, healing usually occurs during a<br />further four weeks treatment period. In patients with poorly responsive gastric ulcer Aciloc 40 mg once<br />daily is recommended and healing is usually achieved within eight weeks.</p><p>Prevention of relapse of gastric ulcers</p><p>For the prevention of relapse in patients with poorly responsive gastric ulcer the recommended dose is<br />Aciloc 20 mg once daily. If needed the dose can be increased to Aciloc 40 mg once daily.</p><p>H. pylori eradication in peptic ulcer disease</p><p>For the eradication of H. pylori the selection of antibiotics should consider the individual patient&#39;s drug<br />tolerance, and should be undertaken in accordance with national, regional and local resistance patterns and<br />treatment guidelines.</p><p>&bull; Aciloc 20 mg + clarithromycin 500 mg + amoxicillin 1,000 mg, each twice daily for one week, or<br />&bull; Aciloc 20 mg + clarithromycin 250 mg (alternatively 500 mg) + metronidazole 400 mg (or 500 mg or<br />tinidazole 500 mg), each twice daily for one week or<br />&bull; Aciloc 40 mg once daily with amoxicillin 500 mg and metronidazole 400 mg (or 500 mg or tinidazole<br />500 mg), both three times a day for one week.</p><p>In each regimen, if the patient is still H. pylori positive, therapy may be repeated.</p><p>Treatment of NSAID-associated gastric and duodenal ulcers</p><p>For the treatment of NSAID-associated gastric and duodenal ulcers, the recommended dose is Aciloc 20<br />mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully<br />healed after the initial course, healing usually occurs during a further four weeks treatment period.</p><p>Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</p><p>For the prevention of NSAID-associated gastric ulcers or duodenal ulcers in patients at risk (age&gt; 60,<br />previous history of gastric and duodenal ulcers, previous history of upper GI bleeding) the recommended<br />dose is Aciloc 20 mg once daily.</p><p>Treatment of reflux oesophagitis<br />The recommended dose is Aciloc 20 mg once daily. In most patients healing occurs within four weeks.<br />For those patients who may not be fully healed after the initial course, healing usually occurs during a<br />further four weeks treatment period.</p><p>In patients with severe oesophagitis Aciloc 40 mg once daily is recommended and healing is usually<br />achieved within eight weeks.</p><p>Long-term management of patients with healed reflux oesophagitis</p><p>For the long-term management of patients with healed reflux oesophagitis the recommended dose is<br />Aciloc 10 mg once daily. If needed, the dose can be increased to Aciloc 20-40 mg once daily.</p><p>Treatment of symptomatic gastro-oesophageal reflux disease</p><p>The recommended dose is Aciloc 20 mg daily. Patients may respond adequately to 10 mg daily, and<br />therefore individual dose adjustment should be considered.</p><p>If symptom control has not been achieved after four weeks treatment with Aciloc 20 mg daily, further<br />investigation is recommended.</p><p>Treatment of Zollinger-Ellison syndrome</p><p>In patients with Zollinger-Ellison syndrome the dose should be individually adjusted and treatment<br />continued as long as clinically indicated. The recommended initial dose is Aciloc 60 mg daily. All<br />patients with severe disease and inadequate response to other therapies have been effectively controlled<br />and more than 90% of the patients maintained on doses of Aciloc 20-120 mg daily. When dose exceed<br />Aciloc 80 mg daily, the dose should be divided and given twice daily.</p><p>Paediatric population</p><p>Children over 1 year of age and &ge; 10 kg</p><p>Treatment of reflux oesophagitis</p><p>Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease</p><p>The posology recommendations are as follows:</p><p>Age Weight Posology</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Age</td><td>Weight</td><td>Posology</td></tr><tr><td>&ge; 1 year of age</td><td>10-20 kg</td><td>10 mg once daily. The dose can be increased to 20 mg once daily if needed</td></tr><tr><td>&ge; 2 years of age</td><td>&gt; 20 kg</td><td>20 mg once daily. The dose can be increased to 40 mg once daily if needed</td></tr></tbody></table><p>Reflux oesophagitis: The treatment time is 4-8 weeks.</p><p>Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease: The<br />treatment time is 2&ndash;4 weeks. If symptom control has not been achieved after 2&ndash;4 weeks the patient should<br />be investigated further.</p><p>Children and adolescents over 4 years of age</p><p>Treatment of duodenal ulcer caused by H. pylori</p><p>When selecting appropriate combination therapy, consideration should be given to official national,<br />regional and local guidance regarding bacterial resistance, duration of treatment (most commonly 7 days<br />but sometimes up to 14 days), and appropriate use of antibacterial agents.</p><p>The treatment should be supervised by a specialist.</p><p>The posology recommendations are as follows:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp; &nbsp; Weight</td><td>Posology</td></tr><tr><td>15&ndash;30 kg</td><td>Combination with two antibiotics: Aciloc 10 mg, amoxicillin 25 mg/kg body weight and clarithromycin 7.5 mg/kg body weight are all administered together two times daily for one week.</td></tr><tr><td>&nbsp; &nbsp; 31&ndash;40 kg</td><td>Combination with two antibiotics: Aciloc 20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administered two times daily for one week.</td></tr><tr><td>&nbsp; &nbsp; &nbsp;&gt; 40 kg</td><td>Combination with two antibiotics: Aciloc 20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administered two times daily for one week.</td></tr></tbody></table><p>Special populations<br />Renal impairment<br />Dose adjustment is not needed in patients with impaired renal function (see section 5.2).<br />Hepatic impairment<br />In patients with impaired hepatic function a daily dose of 10&ndash;20 mg may be sufficient (see section 5.2).<br />Elderly<br />Dose adjustment is not needed in the elderly (see section 5.2).</p><p>Method of administration<br />It is recommended to take Aciloc capsules in the morning, preferably without food, swallowed<br />whole with half a glass of water. The capsules must not be chewed or crushed.</p><p>For patients with swallowing difficulties and for children who can drink or swallow semi-solid food<br />Patients can open the capsule and swallow the contents with half a glass of water or after mixing<br />the contents in a slightly acidic fluid e.g., fruit juice or applesauce, or in non-carbonated water.<br />Patients should be advised that the dispersion should be taken immediately (or within 30 minutes)<br />and always be stirred just before drinking and rinsed down with half a glass of water.</p><p>Alternatively patients can suck the capsule and swallow the pellets with half a glass of water. The<br />enteric-coated pellets must not be chewed..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Omeprazole, substituted benzimidazoles or to any of the excipients.
Omeprazole like other proton pump inhibitors (PPIs) must not be used concomitantly with
nelfinavir (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors<br />(PPIs) like omeprazole for at least three months, and in most cases for a year. Serious<br />manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions,<br />dizziness and ventricular arrhythmia can occur but they may begin insidiously and be<br />overlooked. In most affected patients, hypomagnesaemia improved after magnesium<br />replacement and discontinuation of the PPI.<br />For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs<br />that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider<br />measuring magnesium levels before starting PPI treatment and periodically during<br />treatment.<br />Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year),</p><p>may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly<br />or in presence of other recognised risk factors. Observational studies suggest that proton<br />pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase<br />may be due to other risk factors. Patients at risk of osteoporosis should receive care<br />according to current clinical guidelines and they should have an adequate intake of vitamin<br />D and calcium.<br />In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent<br />vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present,<br />malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.<br />Co-administration of atazanavir with proton pump inhibitors is not recommended (see section<br />4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close<br />clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of<br />atazanavir to 400 mg with 100 mg of ritonavir; Omeprazole 20 mg should not be exceeded.<br />Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin<br />B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with<br />reduced body stores or risk factors for reduced vitamin B12absorption on long-term therapy.<br />Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with Omeprazole, the<br />potential for interactions with drugs metabolised through CYP2C19 should be considered. An<br />interaction is observed between clopidogrel and Omeprazole (see section 4.5). The clinical<br />relevance of this interaction is uncertain. As a precaution, concomitant use of Omeprazole and<br />clopidogrel should be discouraged.</p><p>Interference with laboratory tests<br />Increased CgA level may interfere with investigations for neuroendocrine tumours. To avoid this<br />interference the Omeprazole treatment should be temporarily stopped five days before CgA<br />measurements.<br />Some children with chronic illnesses may require long-term treatment although it is not<br />recommended.<br />Aciloc 40 contains lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.<br />Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal<br />infections such asSalmonella and Campylobacter (see section 5.1).<br />As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of Omeprazole on the pharmacokinetics of other active substances<br />Active substances with pH dependent absorption<br />The decreased intragastric acidity during treatment with Omeprazole might increase or decrease<br />the absorption of active substances with a gastric pH dependent absorption.<br />Nelfinavir, atazanavir<br />The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with<br />Omeprazole.<br />Concomitant administration of Omeprazole with nelfinavir is contraindicated (see section 4.3). Coadministration<br />of Omeprazole (40 mg once daily) reduced mean nelvinavir exposure by ca. 40%<br />and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75 &ndash;<br />90%. The interaction may also involve CYP2C19 inhibition.<br />Concomitant administration of Omeprazole with atazanavir is not recommended (see section 4.4).<br />Concomitant administration of Omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir<br />100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing<br />the atazanavir dose to 400 mg did not compensate for the impact of Omeprazole on atazanavir<br />exposure. The co-administration of Omeprazole (20 mg once daily) with atazanavir 400<br />mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the<br />atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.<br />Digoxin<br />Concomitant treatment with Omeprazole (20 mg daily) and digoxin in healthy subjects increased<br />the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However caution<br />should be exercised when Omeprazole is given at high doses in elderly patients. Therapeutic<br />drug monitoring of digoxin should be then be reinforced.<br />Clopidogrel<br />In a crossover clinical study, clopidogrel (300 mg loading dose followed by 75 mg/day) alone and<br />with Omeprazole (80 mg at the same time as clopidogrel) were administered for 5 days. The<br />exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5)<br />when clopidogrel and Omeprazole were administered together. Mean inhibition of platelet</p><p>aggregation (IPA) was diminished by 47% (24 hours) and 30% (Day 5) when clopidogrel and<br />Omeprazole were administered together. In another study it was shown that administering<br />clopidogrel and Omeprazole at different times did not prevent their interaction that is likely to be<br />driven by the inhibitory effect of Omeprazole on CYP2C19. Inconsistent data on the clinical<br />implications of this PK/PD interaction in terms of major cardiovascular events have been reported<br />from observational and clinical studies.<br />Other active substances<br />The absorption of posaconazole, erlotinib, ketoconazol and itraconazol is significantly reduced<br />and thus clinical efficacy may be impaired. For posaconazol and erlotinib concomitant use should<br />be avoided.<br />Active substances metabolised by CYP2C19<br />Omeprazole is a moderate inhibitor of CYP2C19, the major Omeprazole metabolising enzyme.<br />Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be<br />decreased and the systemic exposure to these substances increased. Examples of such drugs<br />are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.<br />Cilostazol<br />Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased<br />Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by<br />29% and 69% respectively.<br />Phenytoin<br />Monitoring phenytoin plasma concentration is recommended during the first two weeks after<br />initiating Omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a<br />further dose adjustment should occur upon ending Omeprazole treatment.<br />Unknown mechanism<br />Saquinavir<br />Concomitant administration of Omeprazole with saquinavir/ritonavir resulted in increased plasma<br />levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected<br />patients.</p><p>Tacrolimus<br />Concomitant administration of Omeprazole has been reported to increase the serum levels of<br />tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function<br />(creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.<br />Effects of other active substances on the pharmacokinetics of Omeprazole<br />Inhibitors CYP2C19 and/or CYP3A4<br />Since Omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit<br />CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased<br />Omeprazole serum levels by decreasing Omeprazole&#39;s rate of metabolism. Concomitant<br />voriconazole treatment resulted in more than doubling of the Omeprazole exposure. As high<br />doses of Omeprazole have been well-tolerated adjustment of the Omeprazole dose is not<br />generally required. However, dose adjustment should be considered in patients with severe<br />hepatic impairment and if long-term treatment is indicated.<br />Inducers of CYP2C19 and/or CYP3A4<br />Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St<br />John&#39;s wort) may lead to decreased Omeprazole serum levels by increasing Omeprazole&#39;s rate of<br />metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Results from three prospective epidemiological studies (more than 1000 exposed outcomes)<br />indicate no adverse effects of Omeprazole on pregnancy or on the health of the foetus/newborn<br />child. Omeprazole can be used during pregnancy.<br />Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic<br />doses are used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aciloc 40 is not likely to affect the ability to drive or use machines. Adverse drug reactions such<br />as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not<br />drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most common side effects (1-10% of patients) are headache, abdominal pain, constipation, diarrhoea,<br />flatulence and nausea/vomiting.<br />Tabulated list of adverse reactions<br />The following adverse drug reactions have been identified or suspected in the clinical trials programme<br />for omeprazole and post-marketing. None was found to be dose-related. Adverse reactions listed below<br />are classified according to frequency and System Organ Class (SOC). Frequency categories are defined<br />according to the following convention: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon<br />(&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be<br />estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>SOC/frequency</td><td>Adverse reaction</td></tr><tr><td colspan="2">Blood and lymphatic system disorders</td></tr><tr><td>Rare:</td><td>Leukopenia, thrombocytopenia</td></tr><tr><td>Very rare:</td><td>Agranulocytosis, pancytopenia</td></tr><tr><td colspan="2">Immune system disorders</td></tr><tr><td>Rare:</td><td>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</td></tr><tr><td colspan="2">Metabolism and nutrition disorders&nbsp;</td></tr><tr><td>Rare:</td><td>Hyponatraemia</td></tr><tr><td>Not known:</td><td>Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia.<br />Hypomagnesaemia may also be associated with hypokalaemia.</td></tr><tr><td colspan="2">Psychiatric disorders&nbsp;</td></tr><tr><td>Uncommon:</td><td>Insomnia</td></tr><tr><td>Rare:</td><td>Agitation, confusion, depression</td></tr><tr><td>Very rare:</td><td>Aggression, hallucinations</td></tr><tr><td colspan="2">Nervous system disorders</td></tr><tr><td>Common:</td><td>Headache</td></tr><tr><td>Uncommon:</td><td>Dizziness, paraesthesia, somnolence</td></tr><tr><td>Rare:</td><td>Taste disturbance</td></tr><tr><td colspan="2">Eye disorders&nbsp;</td></tr><tr><td>Rare:</td><td>Blurred vision</td></tr><tr><td colspan="2">Ear and labyrinth disorders&nbsp;</td></tr><tr><td>Uncommon:</td><td>Vertigo</td></tr><tr><td colspan="2">Respiratory, thoracic and mediastinal disorders&nbsp;</td></tr><tr><td>Rare:</td><td>Bronchospasm</td></tr><tr><td colspan="2">Gastrointestinal disorders</td></tr><tr><td>Common:</td><td>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland<br />polyps (benign)</td></tr><tr><td>Rare:</td><td>Dry mouth, stomatitis, gastrointestinal candidiasis</td></tr><tr><td>Not known:</td><td>Microscopic colitis</td></tr><tr><td colspan="2">Hepatobiliary disorders&nbsp;</td></tr><tr><td>Uncommon:</td><td>Increased liver enzymes</td></tr><tr><td>Rare:</td><td>Hepatitis with or without jaundice</td></tr><tr><td>Very rare:</td><td>Hepatic failure, encephalopathy in patients with pre-existing liver disease</td></tr><tr><td colspan="2">Skin and subcutaneous tissue disorders</td></tr><tr><td>Uncommon:</td><td>Dermatitis, pruritus, rash, urticaria</td></tr><tr><td>Rare:</td><td>Alopecia, photosensitivity</td></tr><tr><td>Very rare:</td><td>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis<br />(TEN)</td></tr><tr><td>Not known:</td><td>Subacute cutaneous lupus erythematosus (see section 4.4)</td></tr><tr><td colspan="2">Musculoskeletal and connective tissue disorders&nbsp;</td></tr><tr><td>Uncommon:</td><td>Fracture of the hip, wrist or spine</td></tr><tr><td>Rare:</td><td>Arthralgia, myalgia</td></tr><tr><td>Very rare:</td><td>Muscular weakness</td></tr><tr><td colspan="2">Renal and urinary disorders&nbsp;</td></tr><tr><td>Rare:</td><td>Interstitial nephritis</td></tr><tr><td colspan="2">Reproductive system and breast disorders&nbsp;</td></tr><tr><td>Very rare:</td><td>Gynaecomastia</td></tr><tr><td colspan="2">General disorders and administration site conditions&nbsp;</td></tr><tr><td>Uncommon:</td><td>Malaise, peripheral oedema</td></tr><tr><td>Rare:</td><td>Increased sweating</td></tr></tbody></table><p>Paediatric population<br />The safety of omeprazole has been assessed in a total of 310 children aged 0 to 16 years with acid-related<br />disease. There are limited long-term safety data from 46 children who received maintenance therapy of<br />omeprazole during a clinical study for severe erosive oesophagitis for up to 749 days. The adverse event</p><p>profile was generally the same as for adults in short- as well as in long-term treatment. There are no longterm<br />data regarding the effects of omeprazole treatment on puberty and growth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of omeprazole in humans. In the<br />literature, doses of up to 560 mg have been described, and occasional reports have been received when<br />single oral doses have reached up to 2,400 mg omeprazole (120 times the usual recommended clinical<br />dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been reported. Also<br />apathy, depression and confusion have been described in single cases.</p><p>The symptoms described have been transient, and no serious outcome has been reported. The rate of<br />elimination was unchanged (first order kinetics) with increased doses. Treatment, if needed, is<br />symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid-related disorders, proton pump inhibitors, ATC code:<br />A02BC01</p><p>Mechanism of action<br />Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly<br />targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly<br />acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.</p><p>Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic<br />environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H+ K+-<br />ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dosedependent<br />and provides for highly effective inhibition of both basal acid secretion and stimulated acid<br />secretion, irrespective of stimulus.</p><p>Pharmacodynamic effects<br />All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.<br />Effect on gastric acid secretion</p><p>Oral dosing with omeprazole once daily provides for rapid and effective inhibition of daytime and nighttime<br />gastric acid secretion with maximum effect being achieved within 4 days of treatment. With<br />omeprazole 20 mg, a mean decrease of at least 80% in 24-hour intragastric acidity is then maintained in<br />duodenal ulcer patients, with the mean decrease in peak acid output after pentagastrin stimulation being<br />about 70% 24 hours after dosing.</p><p>Oral dosing with omeprazole 20 mg maintains an intragastric pH of &ge; 3 for a mean time of 17 hours of the<br />24-hour period in duodenal ulcer patients.</p><p>As a consequence of reduced acid secretion and intragastric acidity, omeprazole dose-dependently<br />reduces/normalizes acid exposure of the oesophagus in patients with gastro-oesophageal reflux disease.</p><p>The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of<br />omeprazole and not to the actual plasma concentration at a given time.</p><p>No tachyphylaxis has been observed during treatment with omeprazole.</p><p>Effect on H. pylori<br />H. pylori is associated with peptic ulcer disease, including duodenal and gastric ulcer disease. H. pylori is<br />a major factor in the development of gastritis. H. pylori together with gastric acid are major factors in the<br />development of peptic ulcer disease. H. pylori is a major factor in the development of atrophic gastritis<br />which is associated with an increased risk of developing gastric cancer.</p><p>Eradication of H. pylori with omeprazole and antimicrobials is associated with, high rates of healing and<br />long-term remission of peptic ulcers.</p><p>Dual therapies have been tested and found to be less effective than triple therapies. They could, however,<br />be considered in cases where known hypersensitivity precludes use of any triple combination.</p><p>Other effects related to acid inhibition</p><p>During long-term treatment gastric glandular cysts have been reported in a somewhat increased frequency.<br />These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and<br />appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of<br />bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing drugs may lead to<br />slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and, in<br />hospitalised patients, possibly also Clostridium difficile.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the<br />decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level<br />may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that<br />proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements.<br />This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to<br />reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been<br />observed in some patients (both children and adults) during long term treatment with omeprazole. The<br />findings are considered to be of no clinical significance.</p><p>Paediatric population<br />In a non-controlled study in children (1 to 16 years of age) with severe reflux oesophagitis, omeprazole at<br />doses of 0.7 to 1.4 mg/kg improved oesophagitis level in 90% of the cases and significantly reduced reflux<br />symptoms. In a single-blind study, children aged 0&ndash;24 months with clinically diagnosed gastrooesophageal<br />reflux disease were treated with 0.5, 1.0 or 1.5 mg omeprazole/kg. The frequency of<br />vomiting/regurgitation episodes decreased by 50% after 8 weeks of treatment irrespective of the dose.</p><p>Eradication of H. pylori in children<br />A randomised, double blind clinical study (H&eacute;liot study) concluded that omeprazole in combination with<br />two antibiotics (amoxicillin and clarithromycin), was safe and effective in the treatment of H.<br />pylori infection in children age 4 years old and above with gastritis: H. pylori eradication rate: 74.2%<br />(23/31 patients) with omeprazole + amoxicillin + clarithromycin versus 9.4% (3/32 patients) with<br />amoxicillin + clarithromycin. However, there was no evidence of any clinical benefit with respect to<br />dyspeptic symptoms. This study does not support any information for children aged less than 4</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Omeprazole and omeprazole magnesium are acid labile and are therefore administered orally as<br />enteric-coated granules in capsules or tablets. Absorption of omeprazole is rapid, with peak plasma<br />levels occurring approximately 1-2 hours after dose. Absorption of omeprazole takes place in the<br />small intestine and is usually completed within 3-6 hours. Concomitant intake of food has no influence<br />on the bioavailability. The systemic availability (bioavailability) from a single oral dose of omeprazole<br />is approximately 40%. After repeated once-daily administration, the bioavailability increases to about 60%.</p><p>Distribution<br />The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight.<br />Omeprazole is 97% plasma protein bound.</p><p>Biotransformation<br />Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of its<br />metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation<br />of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another<br />specific isoform, CYP3A4, responsible for the formation of omeprazole sulfone. As a consequence of<br />high affinity of omeprazole to CYP2C19, there is a potential for competitive inhibition and metabolic<br />drug-drug interactions with other substrates for CYP2C19. However, due to low affinity to CYP3A4,<br />omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates. In addition,<br />omeprazole lacks an inhibitory effect on the main CYP enzymes.</p><p>Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional<br />CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of omeprazole<br />is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 20 mg<br />omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in subjects having a<br />functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were also<br />higher, by 3 to 5 times. These findings have no implications for the posology of omeprazole.</p><p>Elimination<br />The plasma elimination half-life of omeprazole is usually shorter than one hour both after single and<br />repeated oral once-daily dosing. Omeprazole is completely eliminated from plasma between doses<br />with no tendency for accumulation during once-daily administration. Almost 80% of an oral dose of<br />omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily originating<br />from bile secretion.</p><p>Linearity/non-linearity<br />The AUC of omeprazole increases with repeated administration. This increase is dose-dependent and<br />results in a non-linear dose-AUC relationship after repeated administration. This time- and dosedependency<br />is due to a decrease of first pass metabolism and systemic clearance probably caused by<br />an inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g. the sulfone).</p><p>No metabolite has been found to have any effect on gastric acid secretion.<br />Special populations</p><p>Hepatic impairment<br />The metabolism of omeprazole in patients with liver dysfunction is impaired, resulting in an increased<br />AUC. Omeprazole has not shown any tendency to accumulate with once daily dosing.</p><p>Renal impairment<br />The pharmacokinetics of omeprazole, including systemic bioavailability and elimination rate, are<br />unchanged in patients with reduced renal function.</p><p>Elderly<br />The metabolism rate of omeprazole is somewhat reduced in elderly subjects (75-79 years of age).</p><p>Paediatric population<br />During treatment with the recommended doses to children from the age of 1 year, similar plasma<br />concentrations were obtained as compared to adults. In children younger than 6 months, clearance<br />of omeprazole is low due to low capacity to metabolize omeprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with<br />omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition.<br />Similar findings have been made after treatment with H2-receptor antagonists, proton pump inhibitors and<br />after partial fundectomy. Thus, these changes are not from a direct effect of any individual active<br />substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Sucrose<br />Disodium hydrogen<br />phosphate<br />Sodium Lauryl<br />sulphate<br />Lactose<br />Calcium Carbonate<br />Hydroxy propyl methy<br />Cellulose<br />Methacrylic acid<br />Propylene glycol<br />Diethyl phthalate<br />Cetyl alcohol<br />Sodium hydroxide<br />Tween-80<br />Pvpk-30<br />Titanium dioxide<br />Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.Protect from light</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary :<br />Immediate container: Alu-Alu printed blister strip.<br />Secondary:<br />Outer individual carton<br />PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JAMJOOM PHARMACEUTICALS COMPANY
P.O Box 6267
Jeddah 21442
Tel : +966-12-6081111
Fax: +966-12-6081222
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct-2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>